Seoul Pharma Co. Ltd (018680) - Net Assets
Based on the latest financial reports, Seoul Pharma Co. Ltd (018680) has net assets worth ₩41.30 Billion KRW (≈ $27.99 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩74.00 Billion ≈ $50.15 Million USD) and total liabilities (₩32.70 Billion ≈ $22.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Seoul Pharma Co. Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩41.30 Billion |
| % of Total Assets | 55.81% |
| Annual Growth Rate | 3.9% |
| 5-Year Change | 39.23% |
| 10-Year Change | 19.81% |
| Growth Volatility | 31.79 |
Seoul Pharma Co. Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Seoul Pharma Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Seoul Pharma Co. Ltd (018680) total assets for the complete picture of this company's asset base.
Annual Net Assets for Seoul Pharma Co. Ltd (2012–2024)
The table below shows the annual net assets of Seoul Pharma Co. Ltd from 2012 to 2024. For live valuation and market cap data, see 018680 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩40.17 Billion ≈ $27.22 Million |
+4.17% |
| 2023-12-31 | ₩38.56 Billion ≈ $26.13 Million |
+8.87% |
| 2022-12-31 | ₩35.42 Billion ≈ $24.00 Million |
+86.85% |
| 2021-12-31 | ₩18.96 Billion ≈ $12.85 Million |
-34.29% |
| 2020-12-31 | ₩28.85 Billion ≈ $19.55 Million |
+1.41% |
| 2019-12-31 | ₩28.45 Billion ≈ $19.28 Million |
-43.45% |
| 2018-12-31 | ₩50.31 Billion ≈ $34.10 Million |
-6.58% |
| 2017-12-31 | ₩53.86 Billion ≈ $36.50 Million |
+28.02% |
| 2016-12-31 | ₩42.07 Billion ≈ $28.51 Million |
+25.47% |
| 2015-12-31 | ₩33.53 Billion ≈ $22.72 Million |
+7.81% |
| 2014-12-31 | ₩31.10 Billion ≈ $21.08 Million |
-3.57% |
| 2013-12-31 | ₩32.25 Billion ≈ $21.86 Million |
+27.06% |
| 2012-12-31 | ₩25.38 Billion ≈ $17.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Seoul Pharma Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩4.75 Billion | 11.82% |
| Common Stock | ₩5.83 Billion | 14.51% |
| Other Components | ₩29.59 Billion | 73.66% |
| Total Equity | ₩40.17 Billion | 100.00% |
Seoul Pharma Co. Ltd Competitors by Market Cap
The table below lists competitors of Seoul Pharma Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jullundur Motor Agency (Delhi) Limited
NSE:JMA
|
$22.30 Million |
|
RIAS A/S
CO:RIAS-B
|
$22.30 Million |
|
Hoftex Group AG
MU:NBH
|
$22.32 Million |
|
Starbreeze AB (publ)
ST:STAR-B
|
$22.33 Million |
|
Condor Resources Inc
V:CN
|
$22.26 Million |
|
Lyka Labs Limited
NSE:LYKALABS
|
$22.26 Million |
|
Maternus-Kliniken Aktiengesellschaft
F:MAK
|
$22.26 Million |
|
Talam Transform Bhd
KLSE:2259
|
$22.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seoul Pharma Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 38,564,140,970 to 40,171,982,580, a change of 1,607,841,610 (4.2%).
- Net income of 1,698,603,290 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.70 Billion | +4.23% |
| Other Changes | ₩-90.76 Million | -0.23% |
| Total Change | ₩- | 4.17% |
Book Value vs Market Value Analysis
This analysis compares Seoul Pharma Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.82x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.50x to 0.82x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5684.70 | ₩2820.00 | x |
| 2017-12-31 | ₩6423.27 | ₩2820.00 | x |
| 2018-12-31 | ₩5929.40 | ₩2820.00 | x |
| 2019-12-31 | ₩3352.84 | ₩2820.00 | x |
| 2020-12-31 | ₩3384.64 | ₩2820.00 | x |
| 2021-12-31 | ₩2223.90 | ₩2820.00 | x |
| 2022-12-31 | ₩3038.06 | ₩2820.00 | x |
| 2023-12-31 | ₩3307.58 | ₩2820.00 | x |
| 2024-12-31 | ₩3445.48 | ₩2820.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seoul Pharma Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.17%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.78x
- Recent ROE (4.23%) is above the historical average (-5.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -2.24% | -1.59% | 0.55x | 2.54x | ₩-3.81 Billion |
| 2015 | -2.34% | -1.75% | 0.54x | 2.47x | ₩-4.14 Billion |
| 2016 | 1.94% | 1.78% | 0.50x | 2.20x | ₩-3.39 Billion |
| 2017 | 1.64% | 1.89% | 0.54x | 1.61x | ₩-4.50 Billion |
| 2018 | -8.65% | -9.86% | 0.49x | 1.80x | ₩-9.39 Billion |
| 2019 | -6.57% | -3.46% | 0.76x | 2.49x | ₩-4.71 Billion |
| 2020 | -4.65% | -2.57% | 0.80x | 2.26x | ₩-4.23 Billion |
| 2021 | -51.11% | -23.94% | 0.65x | 3.28x | ₩-11.58 Billion |
| 2022 | 2.41% | 1.71% | 0.80x | 1.76x | ₩-2.69 Billion |
| 2023 | 9.12% | 6.70% | 0.83x | 1.64x | ₩-339.08 Million |
| 2024 | 4.23% | 3.17% | 0.75x | 1.78x | ₩-2.32 Billion |
Industry Comparison
This section compares Seoul Pharma Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $440,493,390,371
- Average return on equity (ROE) among peers: 2.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seoul Pharma Co. Ltd (018680) | ₩41.30 Billion | -2.24% | 0.79x | $22.28 Million |
| Dongwha Pharm.Co.Ltd (000020) | $360.13 Billion | 4.96% | 0.24x | $112.70 Million |
| Yuhan Corp. (000100) | $1.07 Trillion | 11.67% | 0.17x | $4.51 Billion |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $58.60 Million |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $90.54 Billion | 5.22% | 0.52x | $17.71 Million |
| Yuyu Pharma Inc (000227) | $71.49 Billion | -10.45% | 0.42x | $42.97 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $74.84 Million |
| Samil Pharm (000520) | $55.42 Billion | -20.19% | 0.95x | $132.07 Million |
| Donga Socio Holdings (000640) | $190.87 Billion | 12.43% | 2.11x | $429.77 Million |
| Jw Pharmac (001060) | $225.76 Billion | 14.13% | 1.78x | $469.14 Million |
About Seoul Pharma Co. Ltd
Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more